Pancreatic Cancer Trial, Recruiting NCT06287749 Sponsor: University Hospital, Montpellier Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT06287749
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma, confirmed by a specialist medical team.
  • People aged 18 years or older.
  • People who are scheduled to have surgery with the goal of fully removing the cancer.

Who may not be able to join:

  • People whose pancreatic cancer is inherited (runs in the family due to genetics).
  • People who have been confirmed to have cancer that has spread to other parts of the body.
  • People who the trial investigators believe are unlikely to follow the trial plan, attend follow-up visits, or complete the study.
  • People who have had another type of cancer (not counting previous pancreatic cancer, or certain non-melanoma skin cancers) within the 3 years before the eligibility screening.
  • People who are pregnant, breastfeeding, or of childbearing age and not willing to use contraception during the trial.
  • People who are under a legal guardianship or protection order (confirm with trial site).
  • People who do not have health insurance coverage.
  • People who are unable to understand or sign a written consent form for the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Thomas BARDOL, M.D., University Hospital, Montpellier

Phone: +33411759931

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
31 October 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

3-year Disease-free survival (DFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov